Terrell v. Kiromic Biopharma, Inc.

CourtSupreme Court of Delaware
DecidedMay 4, 2023
Docket299, 2022
StatusPublished

This text of Terrell v. Kiromic Biopharma, Inc. (Terrell v. Kiromic Biopharma, Inc.) is published on Counsel Stack Legal Research, covering Supreme Court of Delaware primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
Terrell v. Kiromic Biopharma, Inc., (Del. 2023).

Opinion

IN THE SUPREME COURT OF THE STATE OF DELAWARE

JASON TERRELL, § § No. 299, 2022 Plaintiff Below, § Appellant, § Court Below: Court of Chancery § of the State of Delaware v. § § C.A. No. 2021-0248 KIROMIC BIOPHARMA, INC., § § Defendant Below, § Appellee. §

Submitted: February 8, 2023 Decided: May 4, 2023

Before SEITZ, Chief Justice; VALIHURA and TRAYNOR, Justices.

Upon appeal from the Court of Chancery. REVERSED AND REMANDED.

Scott James Leonhardt, Esquire, Jason A. Gibson, Esquire, THE ROSNER LAW GROUP LLC, Wilmington, Delaware; Alexander Klein, Esquire, (argued) BARKET EPSTEIN KEARON ALDEA & LOTURCO, LLP, Garden City, New York, for Appellant Jason Terrell.

Laurence V. Cronin, Esquire, Kelly A. Green, Esquire, SMITH, KATZENSTEIN & JENKINS, LLP, Wilmington, Delaware; Robert S. Friedman, Esquire, Joshua I. Schlenger, Esquire (argued), Katherine Anne Boy Skipsey, Esquire, SHEPPARD, MULLIN, RICHTER & HAMPTON, LLP, New York, New York, for Appellee Kiromic Biopharma, Inc. TRAYNOR, Justice:

In an action seeking declaratory and injunctive relief, the Court of Chancery

was asked to resolve a dispute between a company and one of its former directors

over the meaning of a stock option agreement and option grant notice. Applying the

plain text of the agreement, the Court of Chancery determined that the dispute was

to be resolved in accordance with a board committee’s interpretation of the

agreement and notice. After the board, acting through a committee, interpreted the

agreement and notice in a manner favorable to the company, the Court of Chancery,

without hearing further from the former director, promptly dismissed the former

director’s complaint for lack of subject matter jurisdiction.

In this opinion, we hold that the Court of Chancery properly stayed the action

to permit the board’s committee to interpret the agreement and notice in the first

instance. We disagree, however, with the court’s decision to dismiss the former

director’s complaint without any meaningful review of the committee’s

interpretation. We therefore reverse the Court of Chancery’s order of dismissal and

remand for a review of the committee’s conclusions consistent with the guidance

provided in this opinion.

2 I

A

Dr. Jason Terrell is a former consultant to and director of Kiromic Biopharma,

Inc., a Texas-based biopharmaceutical company incorporated in Delaware.1 He

initially joined Kiromic as an outside consultant in 2014 before joining the

company’s board in 2017. Terrell served on Kiromic’s board until irreconcilable

differences caused him to resign his seat in 2019.

Terrell was compensated for his work at the company through three stock-

option grants, which, following Terrell’s and the Court of Chancery’s lead, we refer

to as Agreements 1, 2, and 3. Agreement 1, which Kiromic and Terrell entered into

on December 10, 2014, in exchange for his consulting services, granted Terrell

options to purchase 500,000 shares of the company’s common stock at a strike price

of $0.50 per share. The exercise term for these options was set to expire on

December 10, 2024.

Agreement 2, entered into on January 23, 2017, to compensate Terrell for his

appointment to the company’s board of directors, extended Terrell the right to

purchase 500,004 shares of common stock at a strike price of $0.17 per share. The

exercise term for this agreement was scheduled to expire on January 23, 2027.

1 We draw the relevant facts from Terrell’s March 22, 2021 Verified Complaint for Declaratory Judgment and Specific Performance and the documents attached to it as exhibits. 3 Terrell received his third, and final, grant of options on November 10, 2017,

in exchange for his commitment to continue serving on the company’s board.

Agreement 3 provided Terrell the option to purchase 500,004 shares of common

stock at a strike price of $0.19 per share and, like the first two agreements, carried

an exercise term of ten years.

Altogether these three stock-option agreements extended Terrell the right to

purchase approximately 1.5 million shares of Kiromic common stock. This number

comports with a 2015 email from Kiromic’s then-CEO to Terrell informing him:

“you will receive in stock options your 500k shares for your consultant [sic] plus the

1 million shares for your position [o]n the board.”2

The dispute in this case arose out of the parties’ competing interpretations of

Agreement 3. This agreement comprises three component parts: a Notice of Stock

Option Grant (the “Grant Notice”), a Stock Option Agreement, and the 2017 Equity

Incentive Plan. It also varies from the first two agreements in two critical respects.

First, Agreement 3, unlike Agreements 1 and 2, contains a provision modifying its

options in the event of a reverse stock split. Stock splits in 2019 and 2020

subsequently revised Terrell’s options under the third agreement to the right to

purchase 14,285 shares of common stock at a strike price of approximately $6.65

per share.

2 App. to Opening Br. at A29. 4 This reduction in value to Agreement 3’s options magnified the agreement’s

second critical difference from the earlier two: the existence of a provision in the

Grant Notice that we will refer to as the “Release.” It is italicized and reads:

By signing this Grant Notice, you acknowledge and agree that other than the Shares [governed by the Grant Notice], you have no other rights to any other options, equity awards or other securities of the Company (except securities of the Company, if any, issued to you on or prior to the date hereof, if any), notwithstanding any commitment or communication regarding options, equity awards or other securities of the Company made prior to the date hereof, whether written or oral, including any reference to the contrary that may be set forth in your offer letter, consultant agreement or other documentation with the Company or any of its predecessors.3 Kiromic believes that this language extinguished Terrell’s right to the options

extended in Agreements 1 and 2, leaving Terrell with the right to purchase only

14,285 shares of the company’s common stock at a strike price of $6.65 per share. 4

Stated differently, it is Kiromic’s position that the option to purchase the 500,004

shares granted in Agreement 3 supplanted the options to purchase the one million

shares granted in Agreements 1 and 2.

Terrell, on the other hand, contends that the parenthetical language, which

excepts from the Release “securities of the Company, if any, issued to you on or

prior to the date hereof, if any[,]” clearly preserves the options granted in

Agreements 1 and 2.5 Terrell therefore maintains that he should have the right to

3 Id. at A35 (italics in original). 4 Id. at A112–13. 5 Id. at A130–31. 5 purchase 500,000 shares of Kiromic common stock at $0.50 per share; 500,004

shares at $0.17 per share; and 14,285 shares at $6.65 per share.

The parties’ divergent interpretations of Agreement 3 prompted Terrell to file

a declaratory-judgment and specific-performance action in the Court of Chancery.

Specifically, Terrell asked the court to declare that Agreements 1 and 2 remained

valid and binding contracts and to compel Kiromic to reserve for the options

provided in them. Kiromic responded by filing a motion to dismiss Terrell’s

complaint for failing to state a claim upon which relief could be granted. The parties’

briefs on Kiromic’s motion addressed their competing interpretations of the Release.

Free access — add to your briefcase to read the full text and ask questions with AI

Related

Airborne Health, Inc. v. Squid Soap, LP
984 A.2d 126 (Court of Chancery of Delaware, 2009)
Dunlap v. State Farm Fire & Casualty Co.
878 A.2d 434 (Supreme Court of Delaware, 2005)
Graham v. State Farm Mutual Automobile Insurance
565 A.2d 908 (Supreme Court of Delaware, 1989)
Public Water Supply Co. v. DiPasquale
735 A.2d 378 (Supreme Court of Delaware, 1999)
Ryan v. Weiner
610 A.2d 1377 (Court of Chancery of Delaware, 1992)
Munyan v. Daimler Chrysler Corp.
909 A.2d 133 (Supreme Court of Delaware, 2006)
Precision Air, Inc. v. Standard Chlorine of Delaware, Inc.
654 A.2d 403 (Supreme Court of Delaware, 1995)
Levinson v. Delaware Compensation Rating Bureau, Inc.
616 A.2d 1182 (Supreme Court of Delaware, 1992)
Gilbert v. El Paso Co.
490 A.2d 1050 (Court of Chancery of Delaware, 1984)
James & Jackson, LLC. v. Willie Gary, LLC.
906 A.2d 76 (Supreme Court of Delaware, 2006)
CIGNA Ins. Co. v. Didimoi Prop. Holdings, NV
110 F. Supp. 2d 259 (D. Delaware, 2000)
Matter of Delmar Box Co.(ætna Ins. Co.)
127 N.E.2d 808 (New York Court of Appeals, 1955)
Ketler v. PFPA, LLC
132 A.3d 746 (Supreme Court of Delaware, 2016)
Gilbert v. El Paso Co.
575 A.2d 1131 (Supreme Court of Delaware, 1990)
Aiu Insurance Company v. Lexes
815 A.2d 312 (Supreme Court of Delaware, 2003)
Martin Marietta Materials, Inc. v. Vulcan Materials Co.
56 A.3d 1072 (Court of Chancery of Delaware, 2012)
Adkins Ltd. Partnership v. O Street Management, LLC
56 A.3d 1159 (District of Columbia Court of Appeals, 2012)
Cambridge Street Metal Co. v. Corrao
566 N.E.2d 1145 (Massachusetts Appeals Court, 1991)

Cite This Page — Counsel Stack

Bluebook (online)
Terrell v. Kiromic Biopharma, Inc., Counsel Stack Legal Research, https://law.counselstack.com/opinion/terrell-v-kiromic-biopharma-inc-del-2023.